Erdafitinib treatment in metastatic urothelial carcinoma: a real-world analysis

Keren Rouvinov*, Eran Levanon, Avivit Peer, Michal Sarfaty, David Sarid, Victoria Neiman, Eduard Grikshtas, Eli Rosenbaum, Igal Kushnir, Barak Talmor, Michael Friger, Yonaton Zarbiv, Eli Gez, Hadas Dresler, Walid Shalata, Amichay Meirovitz, Noa Shani Shrem, Alexander Yakobson, Wilmosh Mermershtain, Daniel Keizman

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


Background: Erdafitinib, a fibroblast growth factor receptor (FGFR) inhibitor is a standard post chemotherapy advanced treatment line for metastatic urothelial carcinoma harboring FGFR2/3 genomic alterations. It was approved based on a phase 2 clinical trial, revealing a 40% response rate, and 13.8 months overall survival. These FGFR genomic alterations are uncommon. Thus, real-world data on erdafitinb use is scant. We herein describe erdafitinib treatment outcome in a real world patient cohort. Methods: We retrospectively reviewed the data of patients treated with erdafitinib from 9 Israeli medical centers. Results: Twenty-five patients with metastatic urothelial carcinoma (median age 73, 64% male, 80% with visceral metastases) were treated with erdafitinib between January 2020 to October 2022. A clinical benefit (complete response 12%, partial response 32%, stable disease 12%) was seen in 56%. Median progression-free survival was 2.7 months, and median overall survival 6.73 months. Treatment related toxicity ≥ grade 3 occurred in 52%, and 32% discontinued therapy due to adverse events. Conclusions: Erdafitinib therapy is associated with a clinical benefit in the real world setting, and associated with similar toxicity as reported in prospective clinical trials.

Original languageEnglish
Article number1151701
JournalFrontiers in Oncology
StatePublished - 2023


  • erdafitinib
  • fibroblast growth factor receptor (FGFR) inhibitor
  • metastatic urothelial carcinoma
  • real-world analysis
  • treatment


Dive into the research topics of 'Erdafitinib treatment in metastatic urothelial carcinoma: a real-world analysis'. Together they form a unique fingerprint.

Cite this